# US 2012/0252881 A1 · Therapeutic agent for tumor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252881 A1
- Document ID: US20120252881A1
- Status: Published application
- Kind: A1
- Application number: 13/498,771
- Filed: 2010-10-01
- Published: 2012-10-04
- Earliest claimed: 2009-10-01
- Assignees: Asahi Kasei Pharma Corporation; National Cancer Center
- Inventors: Takahiro Ochiya; Ryou-u Takahashi
- Web page: https://patentgrep.com/patent/US20120252881A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2330/10: naturally occurring
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/178: miRNA, siRNA or ncRNA
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides a therapeutic agent for a tumor, particularly a therapeutic agent for drug-resistant cancer, an agent for suppression or prophylaxis of tumor metastasis, and an agent for suppression or prophylaxis of cancer recurrence, containing a nucleic acid containing miR27b or a nucleotide having a nucleotide sequence having an identity of 70% or more with the nucleotide sequence shown by SEQ ID NO: 1 and having a function equivalent to miR27b.

## Claims

### Claim 1

A method of treating a tumor, comprising administering a nucleic acid comprising miR27b or a nucleotide having a nucleotide sequence having an identity of 70% or more with the nucleotide sequence shown by SEQ ID NO: 1 and having a function equivalent to miR27b.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the nucleic acid is single stranded or double stranded.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the miR27b is a nucleotide consisting of the nucleotide sequence shown by SEQ ID NO: 1.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the nucleic acid is an RNA consisting of the nucleotide sequence shown by SEQ ID NO: 1 or a partial sequence thereof, or a modified product thereof.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the nucleic acid is an RNA consisting of the nucleotide sequence shown by SEQ ID NO: 1 or a modified product thereof.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the nucleic acid comprising miR27b is at least one kind of nucleic acid selected from the group consisting of miR27b and a precursor thereof.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the precursor is pri-miRNA or pre-miRNA of miR27b.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the tumor is a drug-resistant cancer.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the tumor is a drug-resistant breast cancer or drug-resistant lung cancer.

### Claim 10 (depends on 1)

The method according to claim 1 for the suppression or prophylaxis of tumor metastasis.

### Claim 11 (depends on 1)

The method according to claim 1 for the suppression or prophylaxis of cancer recurrence.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the cancer is breast cancer or lung cancer.

### Claim 13

A method of treating a tumor, comprising administering (A) a nucleic acid comprising miR27b or a nucleotide having a nucleotide sequence having an identity of 70% or more with the nucleotide sequence shown by SEQ ID NO: 1 and having a function equivalent to miR27b, and (B) an antitumor agent in combination.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the tumor is a drug-resistant cancer.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the tumor is a drug-resistant breast cancer or drug-resistant lung cancer.

### Claim at position 16

16-25. (canceled)
